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Abstract The High-Risk Plaque (HRP) Initiative is a
research and development effort to advance the under-
standing, recognition, and management of asymptomatic
individuals at risk for a near-term atherothrombotic event
such as myocardial infarction or stroke. Clinical studies
using the newest technologies have been initiated,
including the BioImage Study in which novel approaches
are tested in a typical health plan population. Asymp-
tomatic at-risk individuals were enrolled, including a
survey-only group (n=865), a group undergoing tradi-
tional risk factor scoring (n=718), and a group in which
all were assessed for both risk factors and subclinical
atherosclerosis (n=6104). The latter two groups underwent
baseline examination in a dedicated mobile facility equipped
with advanced imaging tools suitable for noninvasive
screening for subclinical atherosclerosis (coronary artery
calcium by computed tomography [CT], carotid and
aortic disease by ultrasound, and ankle-brachial index).
Selected participants were offered advanced imaging
(contrast-enhanced CT, magnetic resonance imaging, and
positron emission tomography/CT). Plasma, PAXgene
RNA, and DNA samples were obtained for biomarker
discovery studies. All individuals will be followed until
600 major atherothrombotic events have occurred in
those undergoing imaging.
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Introduction
Heart attack and large artery stroke are usually caused by
acute thrombosis precipitated by an underlying high-risk
(vulnerable) atherosclerotic plaque [1–4]. The High-Risk
Plaque (HRP) Initiative is a joint research and development
effort to advance our understanding, recognition, and
management of HRP , or rather individuals with HRP [5].
The overarching goal of the HRP Initiative is to find the
asymptomatic adults who are at high risk of a near-term
atherothrombotic event withhout knowing it and offer
timely and adequate preventive care for the benefit of the
individual and the society.
Atherothrombotic cardiovascular disease (CVD) is a
leading cause of death and disability not only in affluent
countries but globally and, as such, has a large economic
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DOI 10.1007/s11883-011-0193-0and public health impact [6, 7]. The mortality of athero-
thrombotic CVD has fallen dramatically in the past
decades, and the prolonged survival with chronic disease
explains why the prevalence, burden, and costs of the
disease remain high [8￿, 9￿￿]. The only effective approach
to limit this undue loss of health and resources is to prevent
the disease from developing in the first place (ie, primary
prevention). Public health initiatives are important [10], but
so is personalized prevention for those at highest risk.
Causal and modifiable risk factors for atherothrombotic
CVD are known and constitute important therapeutic targets
[11], but their ability to predict is limited [12]. Most heart
attacks and strokes occur in individuals who would be
classified as low or intermediate risk by the traditional risk
factor–based approaches recommended in the United States
(Framingham Risk Score [13, 14]) and Europe (SCORE
[15]) [16, 17, 18￿]. Conversely, many individuals with an
apparently adverse risk factor profile remain asymptomatic.
Thus, for contemporary medicine to improve, the challenge
is to find and treat those unrecognized individuals at highest
risk without harming those who do not need treatment (ie,
limiting both undertreatment and overtreatment).
Novel circulating biomarkers may provide incremental
prognostic information [19, 20], but their clinical utility
remains to be established [21, 22￿￿]. Despite great promise,
genetic testing for “susceptibility” has not yet proven useful
for risk stratification in clinical practice [22￿￿, 23].
An alternative strategy of potentially greater impact would
be assessment of subclinical (asymptomatic) atherosclerosis
as proposed in recent guidelines [22￿￿]a n d ,i np a r t i c u l a r ,
detection of disease activity and plaques of the high-risk
“vulnerable” type [24–27]. Such lesions are most often
hidden in the arterial wall and not diagnosed until it is too
late. In recent years, studies using advanced imaging
technologies have provided insights into atherosclerotic
plaque development and its progression to vulnerable plaque
and rupture as a cause for acute atherothrombosis leading to
myocardial infarction or stroke [28–31, 32￿￿]. These insights
are providing impetus for the discovery and development of
novel screening and diagnostic tools and potential therapies.
Leading companies and recognized scientists in the field
of cardiovascular disease, radiology, and other medical
disciplines have come together to collectively design, fund,
and execute a number of important studies to discover and
validate methods and tests that will find individuals with
HRP [5]. The goal of this effort, known as the HRP
Initiative, is to identify and validate novel imaging and
blood biomarkers of asymptomatic but high-risk athero-
sclerosis that could be used to spur the development of in
vitro diagnostic tests, medical imaging devices, and
therapeutic products for the more effective identification,
assessment, and treatment of patients at high near-term risk
of a major atherothrombotic event.
The HRP Initiative has initiated a number of important
research studies that use the newest technologies, including
the BioImage Study. In just 18 months, the BioImage Study
completed enrollment of 7,687 participants in June 2009
using a novel and exciting approach for conducting critical
medical research. The BioImage Study brought the study to
the people, rather than using the traditional opposite
approach.
BioImage Study
The BioImage Study (NCT00738725) is a prospective,
observational study designed to evaluate associations among
imaging and circulating biomarkers(cross-sectional) and their
ability to predict atherothrombotic events (longitudinal) in
asymptomatic at-risk subjects in the primary prevention of
myocardial infarction and stroke [33]. In collaboration with
Humana, a large US health benefits company, the BioImage
Study used a unique and innovative approach to identify and
recruit a typical at-risk population (Fig. 1). In contrast to
other large-scale epidemiologic studies that used either a
network of academic research centers or a well-defined
population in a limited geographic area, the BioImage Study
has recruited subjects from two geographic locations
intended to represent the US population at large. In each
location, we established a dedicated temporary research
facility with mobile imaging equipment. The mobile equip-
ment and dedicated staff moved from one location to the
next, facilitating consistency of image acquisition.
As previously highlighted [34], age and gender are the
strongest determinants of cardiovascular risk. Hence, in
designing the BioImage Study, we considered all subjects
over a certain gender-specific age without known cardio-
vascular disease as potential candidates. We included
currently available noninvasive modalities for vascular
imaging, such as ultrasound (US), computed tomography
(CT), magnetic resonance imaging (MRI), and positron
emission tomography (PET). Certain modalities and exami-
nations were limited to certain subsets, whereas others were
used on the overall study population.
The BioImage Study and method of selection and
recruitment were approved by the Western Institutional
Review Board, Olympia, W A. All study participants provided
writteninformedconsentandHealthInsurancePortabilityand
Accountability Act authorization before enrollment.
Study Objectives
The primary objective of the BioImage Study is to identify
imaging biomarkers that predict near-term (3-year) athero-
thrombotic events, with incremental improvement over
traditional risk assessment (Framingham Risk Score). The
360 Curr Atheroscler Rep (2011) 13:359–366secondary objectives of the study are to 1) correlate
imaging data of subclinical atherosclerosis and blood-
based markers, 2) provide standardized high-quality image
sets for the development and refinement of quantitative
digital image analysis, 3) provide standardized high-quality
image sets for the optimization of image protocols and
correction algorithms, 4) compare event rates in patients
randomized to undergo imaging studies with those in
patients who do not undergo such studies, 5) collect and
store biological specimens for future evaluation, 6) postu-
late a novel screening and diagnostic pathway based on the
discovered new risk markers, and 7) acquire pertinent data
for the development of an economic and health impact
model in the primary prevention of CVD. Another
objective of the BioImage Study is to assess possible
lifestyle changes induced by study procedures and knowl-
edge of the presence of subclinical disease.
Targeted at-Risk Population
We wanted to enrich the study population with individuals
with a meaningful probability of developing events in the
near term. To do so, we identified members in the Humana
database who were 55–80 years of age (men>55 years and
women>60 years), as this is the group where most
cardiovascular events occur and where many were expected
to have at least one additional risk factor [34]. Study
participants were recruited among members of the Humana
Health Plan (> 11 million members nationwide) with a male
to female ratio of 1:1 and a racial/ethnic distribution
corresponding to US Census data (approximately 69%
white, 12% African American, 13% Hispanic, 4% Asian,
and 2% other) [35]. To ensure a diverse study population,
enrollment occurred in two cities: Chicago, IL and Fort
Lauderdale, FL.
Recruitment Population Stratified by Claims
Preliminary observations indicate it is possible to risk-
stratify Humana members using information on file,
including medical and pharmacy health insurance claims
[33]. Candidates had to be free of claims-based evidence of
prior major cardiovascular disease, active cancer treatment,
or certain other indicators of major intercurrent disease. We
Fig. 1 Flowchart for the Bio-
Image Study. ABI ankle-brachial
index; CACS coronary artery
calcium score; CTA computed
tomography angiography; MRI
magnetic resonance imaging;
PET-CT positron emission to-
mography–computed tomogra-
phy; US ultrasound
Curr Atheroscler Rep (2011) 13:359–366 361used medical and pharmacy claims to create risk indicators
of established cardiovascular risk, such as medical claims
or prescription medication use for hypertension, diabetes, or
hyperlipidemia. One of the limitations of claims-based risk
assessment is that certain risk factors, such as smoking and
physical inactivity, cannot be determined or inferred from
claims. The most common claims-based risk indicators
were hypertension (65%) and hyperlipidemia (57%). The
majority (57%) had two or more claims-based risk
indicators.
We used medical claims for acute myocardial infarction
and stroke to identify putative major cardiovascular events.
The relationships between claims-based risk indicators and
claims-based event rates are significant [33]. With the
exception of hyperlipidemia, the presence or absence of
specific claims-based risk indicators is also strongly related
with claims-based event rates. Thus, despite the limitations
of claims data, the concept of using claims-based risk
indicators to estimate the average risk of a study population
appears to be valid in individuals in the age range of 55–
80 years without prior history of CVD.
Study Population
Potential study participants were contacted by phone and
interviewed to evaluate eligibility, obtain verbal informed
consent and authorization, and obtain selected personal and
health information. Of those meeting the entrance criteria,
approximately 750 were randomly selected to set aside as
“survey-only group” (no risk assessment). All other individ-
uals meeting the entrance criteria were invited to undergo a
baselineexaminationinadedicatedmobilefacility.Thosewho
agreed to participate were randomized into a Framingham-
only group (traditional risk factor scoring; target n=750) and
the full study group in which all underwent testing for
subclinical atherosclorosis (risk factor scoring plus testing for
subclinical atherosclerosis; target n=6000). Among those in
whom substantial arterial disease was detected, selected
participants were offered advanced imaging for subclinical
atherosclerosis (see Fig. 1).
As part of the informed consent procedure, participants
granted authorization and consent to access their medical/
pharmacy claims and related financial information. Phar-
macy claims will be used to construct the medication
history. In addition, the participants granted consent and
authorization to verify outcomes on the basis of medical
chart review at the facility where such care was provided.
At completion of enrollment in June of 2009, a total of
24,149 Humana members had been surveyed by telephone
or mail, of which 9866 met the eligibility criteria for the
study and agreed to participate. Of this population, 7687
subjects completed enrollment, of which 865 were enrolled
as “survey-only” participants, 718 were enrolled in the
Framingham-only group, and 6104 were enrolled in the full
study group (see Fig. 1).
Generalization of Study Results
As previously described in detail [33], preliminary data from
the Chicago location indicate that the BioImage Study
population is representative of the eligible Chicago population
with respect to age, gender, business line (commercial vs
Medicare), median household income, prevalence of risk
factors, clinical conditions, comorbidities, and prescription
drug use as determined based on medical or pharmacy claims.
Baseline Examination
The examination approach was also novel and proactive,
bringing the necessary research facilities, experienced staff,
and advanced imaging equipments to the study participants
rather than the opposite. The mobile facility consisted of two
dedicated trailers, one containing a 64-slice CT scanner and
the other a 3.0 T MRI scanner. In addition, a fixed building
was used for the other baseline study procedures, including
blood sampling, US imaging, and ABI measurement.
All participants underwent measurement of customary
physical parameters, including height, weight, waist to hip
ratio, brachial blood pressure, ankle blood pressure, and a
12-lead electrocardiogram. A venous blood sample was
processed for the collection of plasma, serum, RNA, and
DNA (stored for later biomarker discovery studies) and
routine chemistry tests (Table 1).
The full study (imaging) group was also screened for
subclinical atherosclerosis, including assessment of coronary
artery calcification score (CACS) by CT, measurement of
carotid intima-media thickness (IMT), presence of carotid
atherosclerotic plaques and abdominal aortic aneurysm
(AAA) by US, and ankle brachial index (ABI) (see Fig. 1).
Subjects who meet one or more predefined criteria for
CACS, carotid IMT, presence of carotid plaque and AAA, or
ABI were offered advanced imaging for subclinical athero-
sclerosis [33]. The choice of advanced imaging method was
based on logistical considerations, patient preference, and
presence/absence of certain clinical criteria that would render
a particular method unsuitable or contraindicated. The
advanced imaging methods included contrast-enhanced or
noncontrast MRI for carotid and aortic plaques, contrast-
enhanced coronary CTangiography for noncalcified plaques
and stenoses, and 18 F-fluorodeoxyglucose PET/CT for
carotid and aortic inflammation.
Notification of Baseline Findings
Study participants were informed that these study-
procedures were conducted for research purposes only
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medical attention would be reported back to the partic-
ipant and their physicians. At the conclusion of the
baseline visit, participants were provided with a summary
of selected findings, including blood pressure, ABI,
presence of carotid artery stenosis, and if the CACS
exceeded the 75% percentile. A letter was mailed to the
participant and their primary care physician with the
routine blood chemistry results. No specific interventions
were offered or recommended.
Surveillance and Event Detection
The study population will be followed until 600 major
atherothrombotic events have occurred in the imaging
group. These primary endpoints for the study include
fatal and nonfatal myocardial infarction, coronary death,
hospitalization for unstable angina (angina at rest with
documented electrocardiographic changes), ischemic
stroke (fatal and nonfatal), and arterial revascularization
procedures (either percutaneous or surgical). Procedure-
related complications are excluded. Potential cardiovas-
cular events will be identified by querying the Humana
claims and member databases for predefined event
triggers at regular intervals throughout the follow-up
period. The claims monitoring for event triggers will be
conducted using Diagnosis-Related Groups (DRG), In-
ternational Classification of Diseases (ICD)-9, and Cur-
rent Procedure Terminology (CPT) codes for myocardial
infarction, cerebrovascular events, unstable angina, pe-
ripheral vascular disease, revascularization procedures,
and all deaths. Use of claims information for these
conditions has previously been validated in numerous
peer-reviewed studies comparing administrative claims
information with clinical information obtained through
chart reviews [36, 37]. Any study participants leaving the
Humana health plan before the end of the follow-up period
will be followed by telephone contact only. The study
participants randomized to the “survey-only” group and
the Humana members included in the two control cohorts
will also be followed through the evaluation of claims and
member data, as described above.
Table 1 Baseline characteristics of participants in selected population studies
Characteristic BioImage
(n=7687)
MESA
(n=6814)
ARIC
(n=15792)
CHS
(n=5201)
Framingham Heart Study
Original
(n=5209)
Offspring
(n=5124)
3rd Generation
(n=4095)
Representative cohort Imaging subset
(n=6101)
Subset
(n=6526)
Subset
(n=13145)
Subset
(n=4536)
Total
(n=5209)
Total
(n=5124)
Total
(n=4094)
Age, y 68.8 (6.0) 62 (10) 54 (5.8) 72.8 44 (9) 36.5 (10.5) 40 (9)
Sex, women,% 56.4 53 56.8 56.7 55.2 51.5 53.3
Race,%
White 74 39 74.8 100
Asian 2 12
Black 15.3 27 25.2
Hispanic 6.1 22
Other 2.6
BMI, kg/m
2 29.1 (5.6) 28.3 (5) 27.36 (5.1) 26.4 (4.5) 25.6 (4.2) 25.2 (4.2) 26.9 (5.4)
Systolic blood pressure, mm Hg 139.5 (18.5) 127 (22) 120.72 (18.6) 135 (21) 135.4 (21.8) 121.9 (16) 116.7 (13.5)
Diastolic blood pressure, mm Hg 78.2 (9.1) 72 (10) 73.46 (11.2) 70 (11) 84.9 (12.6) 78.9 (10.5) 75.3 (9)
Diabetes mellitus,% 15.6 14 10.1 14.5
Current smoker,% 8.5 13 26.1 10.9 57.6 44.5 17.4
Total cholesterol, mg/dL 202.5 (38.7) 194.1 (35.3) 214 (41.4) 212 (40) 221 (44.7) 196.4 (39.5) 188.7 (35.4)
LDL, mg/dL 114.1 (33.3) 117 (32) 136.8 (39.0) 130 (36)
HDL, mg/dL 55.6 (15.3) 51 (15) 52.6 (17.1) 54 (16) 50.2 (13.5) 54.5 (14.1)
Study period 2008–2009 2000–2002 1987–1989 1989–1990 1948–1953 1971–1975 2002–2005
References [39, 40][ 41][ 42][ 43][ 43][ 43]
Data shown as mean (standard deviation) or prevalence %.
ARIC Atherosclerosis Risk In Communities; BMI body mass index; CHS Cardiovascular Health Study; HDL high-density lipoprotein; LDL low-
density lipoprotein; MESA Multi-Ethnic Study of Atherosclerosis
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More than 200 million people in the United States belong
to some form of health insurance plan. The individual’s
personal information and most health care and pharmacy
transactions are known to the plan to adjudicate and pay the
claims. Although the potential for doing studies within the
health care system has long been recognized, few examples
exist where the health care and research chasms have been
successfully bridged, allowing health plans to play a critical
role in addressing an important medical research question.
Study Advantages
The BioImage Study recruited volunteer participants from
Humana’s health plan members, linking their research data
with their broader health care data and then prospectively
using this information to monitor for putative events. This
represents a unique and novel approach that affords many
advantages.
Scale and Pace
The study’s unique mobility combined with capabilities to
quickly identify and recruit large numbers of eligible people
made it possible for the BioImage Study to recruit and
enroll faster than conventional studies. Dedicated, tempo-
rary, and mobile research facilities enabled the use of
multiple advanced imaging modalities within a single
convenient visit for the participants, and also allowed for
the use of a few highly trained and dedicated technicians,
avoiding operator or equipment variability.
Generalization
Geocoding the data using socioeconomic and ethnic
characteristics from the US Census allowed us to enroll
people representative of the US population. The BioImage
Study involves a single baseline set of imaging, clinical,
and biological measurements in a group of US participants
with mostly moderate or high risk. Therefore, conclusions
reached in this study will apply to relatively healthy elderly
individuals, generally with above-average cardiovascular
risk.
Minimizing Recruitment Bias
Possessing data on the entire recruitment population allows
us to identify any selection bias in the enrolled population.
Control cohorts unrelated to the BioImage Study can help
evaluate any bias related to selection criteria, claims-based
risk stratification, and recruitment process or event rate
markers.
Understanding Economic Impact
We have the data needed to analyze the impact of primary
outcomes as well as any influence of the study itself on
utilization patterns of participants.
Other Benefits
One of the benefits of this approach is the ability to judge
how the participants compare with nonparticipants, includ-
ing those who were not invited or those who could not be
reached or declined to participate. The BioImage Study will
be able to answer questions about selection bias as well as
whether the study induced health care changes. In partic-
ular, the risks of selection bias or study-induced provider or
patient behavioral changes are important factors to consider.
As an example, the preliminary results from the Chicago
location regarding risk factor distribution demonstrate a
significant difference in the proportions of individuals with
zero risk factors between study participants and eligible
subjects. This may indicate some selection bias, presumably
due to those volunteering being more concerned about their
health status than other similar individuals from the general
population.
It is difficult to overstate the importance of finding
asymptomatic individuals at near-term risk for atherothrom-
bosis. It is the challenging purpose of the HRP Initiative. A
simple and effective screening test for subclinical athero-
thrombosis could enable effective primary prevention in the
months or years before the first event and has a potential
impact on life expectancy that seems unattainable for any
other major medical condition. It is estimated that the
impact on life expectancyo fs u c hat e s tt oe n a b l e
preventive treatment would be comparable to the eradica-
tion of all forms of cancer [38]. Only recognition and
treatment of at-risk atherosclerosis, not only risk factor
assessment, offer the potential to reduce cardiovascular
morbidity and mortality from its current level.
Limitations
One limitation of the BioImage Study is that only
individuals with health benefit coverage with Humana were
eligible for enrollment and, consequently, no uninsured
individuals were enrolled. When we compared the house-
hold incomes of the insured participants from the Chicago
area, it mirrored those for the state as a whole (insured and
noninsured individuals). However, the uninsured individu-
als, independent of socioeconomic characteristics, have
multiple disadvantages that in themselves are associated
with poor health; hence, the findings of this study may not
be applicable to uninsured individuals. Another limitation is
the absence of traditional physician follow-up and reliance
364 Curr Atheroscler Rep (2011) 13:359–366on administrative data to identify primary outcomes.
However, and as mentioned above, claims-based outcomes
have been extensively validated. Finally, we could not
randomize people for the advanced imaging studies; and
personal preference (eg, dislike for tight spaces, concerns
about administration of contrast agents) or personal health
concerns (eg, desire to know as much as possible) could
have biased participation.
Conclusions
The BioImage Study represents a new model that brings
important medical research to a health plan population and
leverages the health plan data and systems to the benefit of
research. This research model is broadly applicable to
important medical questions that require study of a large
population representing the population-at-large. The Bio-
Image Study has the potential to materially contribute to
our understanding of who is at risk for near-term athero-
thrombosis and enable a new paradigm of early disease
recognition and treatment to augment what is potentially
achievable through risk factor reduction.
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